Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein - PubMed (original) (raw)
Affiliations
- PMID: 9815666
Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein
S R Husain et al. Clin Cancer Res. 1997 Feb.
Abstract
AIDS-associated Kaposi's sarcoma (AIDS-KS), the most common malignant complication of human immunodeficiency virus infection, is characterized by neoplastic proliferation of mesenchymal cells. AIDS-KS cells release and respond to an array of cytokines through specific plasma membrane receptors. Specific targeting of potent cytotoxic agents to cell surface receptors/antigens on Kaposi's sarcoma cells may provide effective therapy for this malignancy. We have identified a new target in the form of an interleukin 13 (IL-13) receptor that is overexpressed in the five AIDS-KS cell lines examined. Radiolabeled IL-13 cross-linked to a single protein of about Mr 70,000 in AIDS-KS cells. We utilized a chimeric cytotoxic protein composed of IL-13 and a truncated Pseudomonas exotoxin (IL13-PE38QQR), which was found to be specifically and highly cytotoxic to AIDS-KS cells, as determined by protein synthesis inhibition and clonogenic assays. IL13-PE38QQR demonstrated significant antitumor activity in a human epidermoid carcinoma xenograft model. Normal human umbilical vein-derived endothelial, lymphoid, and bone marrow precursor cells expressed low levels of IL-13 receptors, and IL-13 toxin was not cytotoxic to them. Thus, IL-13 receptor on AIDS-KS cells may represent a novel plasma membrane protein(s) that could be utilized to target therapeutic agents.
Similar articles
- Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.
Husain SR, Puri RK. Husain SR, et al. Blood. 2000 Jun 1;95(11):3506-13. Blood. 2000. PMID: 10828036 - Cintredekin besudotox in treatment of malignant glioma.
Mut M, Sherman JH, Shaffrey ME, Schiff D. Mut M, et al. Expert Opin Biol Ther. 2008 Jun;8(6):805-12. doi: 10.1517/14712598.8.6.805. Expert Opin Biol Ther. 2008. PMID: 18476792 Review. - hIL-13-PE38QQR. NeoPharm.
Barth S. Barth S. Curr Opin Investig Drugs. 2001 Sep;2(9):1309-13. Curr Opin Investig Drugs. 2001. PMID: 11717820 Review.
Cited by
- The Immunotherapy Landscape in Adrenocortical Cancer.
Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J. Pegna GJ, et al. Cancers (Basel). 2021 May 28;13(11):2660. doi: 10.3390/cancers13112660. Cancers (Basel). 2021. PMID: 34071333 Free PMC article. Review. - Targeting Receptors on Cancer Cells with Protein Toxins.
Antignani A, Ho ECH, Bilotta MT, Qiu R, Sarnvosky R, FitzGerald DJ. Antignani A, et al. Biomolecules. 2020 Sep 17;10(9):1331. doi: 10.3390/biom10091331. Biomolecules. 2020. PMID: 32957689 Free PMC article. Review. - Transcriptional regulation of the IL-13Rα2 gene in human lung fibroblasts.
Penke LR, Ouchi H, Speth JM, Lugogo N, Huang YJ, Huang SK, Peters-Golden M. Penke LR, et al. Sci Rep. 2020 Jan 23;10(1):1083. doi: 10.1038/s41598-020-57972-1. Sci Rep. 2020. PMID: 31974428 Free PMC article. - Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.
Newman JP, Wang GY, Arima K, Guan SP, Waters MR, Cavenee WK, Pan E, Aliwarga E, Chong ST, Kok CYL, Endaya BB, Habib AA, Horibe T, Ng WH, Ho IAW, Hui KM, Kordula T, Lam PYP. Newman JP, et al. Nat Commun. 2017 Dec 4;8(1):1913. doi: 10.1038/s41467-017-01392-9. Nat Commun. 2017. PMID: 29203859 Free PMC article. - IL-13 induces the expression of 11βHSD2 in IL-13Rα2 dependent manner and promotes the malignancy of colorectal cancer.
Jiang L, Cheng Q, Zhang B, Zhang M. Jiang L, et al. Am J Transl Res. 2016 Feb 15;8(2):1064-72. eCollection 2016. Am J Transl Res. 2016. PMID: 27158392 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical